Preliminary phase II results presented at the ERA–EDTA Congress showed that, for patients with stage 3 and 4 chronic kidney disease, mild iron deficiency and mildly elevated serum phosphate levels, ferric citrate coordination complex can increase transferrin saturation, reduce serum phosphate, increase haemoglobin and reduce fibroblast growth factor levels. Adverse events were comparable with placebo at this stage of reporting (12 weeks).
References
Block, G. et al. A double-blind placebo controlled randomized trial of ferric citrate coordination complex for the treatment of iron-deficient anemia and reduction of serum phosphate in patients with non-dialysis dependent chronic kidney disease [abstract 4025]. ERA–EDTA Congress [online], (2014).
Rights and permissions
About this article
Cite this article
Treating iron deficiency and elevated phosphate—new data. Nat Rev Nephrol 10, 422 (2014). https://doi.org/10.1038/nrneph.2014.108
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2014.108
